Further studies show that the blockade of MIF with a neutralizing MIF antibody, small molecule, or a tolerogenic peptide (hCDR1) can also improve renal dysfunction and reduce leukocyte recruitment and inflammatory cytokine production [61,62], confirming the pathogenic role of MIF in LN. Here, MIF is linked to lobular neoplasia.